{"entity":{"id":"sabr-oligometastases","kind":"technology","name":"Stereotactic ablative radiotherapy for oligometastatic disease","aka":[],"tldr":"Treating every visible metastasis with ablative doses when there are only a few, on the idea that some patients with limited spread can still be controlled or cured.","summary":"The oligometastatic hypothesis, proposed in 1995, holds that some cancers spread to a handful of sites before becoming widespread, and that ablating those sites can change the course of the disease. The SABR-COMET randomised phase 2 trial reported in 2019 that stereotactic treatment of one to five metastases lengthened survival compared with standard care, with some added toxicity. Phase 3 trials (SABR-COMET-3 and -10, NRG-BR002 in breast cancer, and prostate-specific studies) are now testing the approach cancer by cancer, and it has become common practice in prostate, lung and kidney cancer with limited spread.","status":"emerging","asOf":"2026-09-17","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Oligometastasis"}],"tags":["radiation-wave1"],"related":[],"cancers":["metastatic-cancer","prostate","nsclc","rcc"],"sections":["radiation"],"technologies":["sbrt","psma-pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["sabr-comet"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Ablative doses to every detectable metastasis, combined with systemic therapy, aim to eliminate the visible disease rather than merely palliate it.","strengths":["Non-invasive ablation of multiple sites","Can delay the next line of systemic therapy","Survival signal in randomised phase 2"],"limitations":["Phase 3 evidence still partial and cancer specific","Depends on sensitive staging (PSMA PET)","Toxicity when targets are near critical organs"],"since":2019},"route":"/technologies/sabr-oligometastases/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"section":[{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"}],"technology":[{"id":"biology-guided-radiotherapy","kind":"technology","name":"Biology-guided radiotherapy (RefleXion X1, SCINTIX)","route":"/technologies/biology-guided-radiotherapy/"},{"id":"cyberknife","kind":"technology","name":"CyberKnife robotic radiosurgery","route":"/technologies/cyberknife/"},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"trial":[{"id":"oriole","kind":"trial","name":"ORIOLE","route":"/trials/oriole/"},{"id":"sabr-comet","kind":"trial","name":"SABR-COMET: stereotactic ablative radiotherapy for oligometastatic cancer","route":"/trials/sabr-comet/"},{"id":"stomp-oligorecurrence","kind":"trial","name":"STOMP","route":"/trials/stomp-oligorecurrence/"}]}}